ASAP reduces costs to a fraction of conventional stability studies…


Posted on September 29, 2017 in

The American Pharmaceutical Review recently published an article in their July/August 2017 issue titled, “An Introduction to the Accelerated Stability Assessment Program (ASAP).” The article concludes that ASAP is “much faster than conventional stability or package screening studies at a higher accuracy.” And that “ASAP is capable of reducing costs to a fraction of conventional stability studies…” The team at FreeThink agrees! Read the complete article.